About PeptideAAA

PeptideAAA is an independent, editorially-run resource that translates peptide and GLP-1 research, regulation, and clinical evidence into plain-English coverage — without selling, distributing, or promoting the use of any compound.

Our Mission

Peptide therapies, from GLP-1 medications to research-grade compounds like BPC-157 and TB-500, generate an enormous amount of hype, marketing, and misinformation. Our mission is to cut through that noise with evidence-first explainers that clearly separate what has strong clinical support from what remains preliminary, animal-only, or anecdotal.

Editorial Approach

Every article on this site is written to summarize publicly available research, regulatory filings (FDA, ClinicalTrials.gov), and peer-reviewed literature. We label speculative or early-stage findings as such, flag when human evidence is thin or absent, and note when a compound is not FDA-approved for human use. Illustrative patient accounts are always identified as composite, educational narratives rather than reports of real individuals. See our full disclaimer for more detail on these editorial standards.

Meet the Publisher

Mike Allen is the publisher of PeptideAAA, overseeing the site's editorial direction, research standards, and content review process. Mike is responsible for ensuring articles published under the PeptideAAA byline meet the site's bar for accuracy, sourcing, and balanced treatment of both the potential and the limitations of peptide research.

Contact

Questions about this site's content, corrections, or editorial inquiries can be directed to the site owner through the contact information provided elsewhere on this domain.